Clinical Trial Detail

NCT ID NCT03374254
Title Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Merck Sharp & Dohme Corp.
Indications

colorectal cancer

Therapies

Fluorouracil + Irinotecan + Leucovorin + Pembrolizumab

Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab

Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab

Binimetinib + Fluorouracil + Irinotecan + Leucovorin + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.